SARS-CoV-2 Spike RBD Nanobody, Clone: A1

Uniprot No.: P0DTC2.

Immunogen: Recombinant Human Novel Coronavirus Spike glycoprotein(S) (319-541aa) (CSB-YP3324GMY1 and CSB-MP3324GMY1b1).

Immunogen Species: Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV).

Purification Method: Affinity-chromatography.

Buffer: Preservative: 0.03% Proclin 300.
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4.

Form: Liquid.

Clone No.: A1.

Description: This SARS-CoV-2 Spike RBD Nanobody is a recombinant monoclonal antibody generated through the expression of a DNA sequence inserting a human IgG1 Fc domain at the C-terminus, in human embryonic kidney 293 cells (HEK293). The DNA sequence encodes the SARS-CoV-2 spike receptor-binding domain (RBD). The antibody is purified by protein G in vitro. It has been validated with high reactivity towards SARS-CoV-2-S1-RBD by a functional ELISA and good sensitivity for human SARS-CoV-2 spike glycoprotein (S protein) via the Colloidal Gold Immunochromatography Assay (GICA). In neutralization assay, the binding signal of SARS-CoV-2 Spike RBD Nanobody was inhibited by ACE2 protein-HRP conjugated inhibitor, with a 0.1074 μg/ml IC50. Specifically binding and recognizing the RBD of the SARS-CoV-2 spike glycoprotein (S protein), so the SARS-CoV-2 Spike RBD Nanobody can react with samples infected with human coronavirus SARS-CoV-2. But it does not respond to MERS or SARS-CoV spike protein. Akin to other nanobodies, this recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.